Adcetris Approved for Pediatric Patients With High-Risk Classical Hodgkin Lymphoma
The approval was based on data from the open-label phase 3 AHOD1331 trial.
The approval was based on data from the open-label phase 3 AHOD1331 trial.
Findings showed that treatment with cemiplimab-rwlc plus platinum-based chemotherapy demonstrated a statistically significant improvement in overall survival.
Omburtamab is an investigational radiolabeled monoclonal antibody designed to target tumor cells that express B7-H3.
Sapanisertib is a dual mTORC 1/2 inhibitor that targets a key survival mechanism in KEAP1/NRF2-mutated tumor cells.
Rolvedon is a long-acting granulocyte colony-stimulating factor.
The patient first noticed a firm, nontender, moveable hard mass while conducting a routine breast self-examination in the shower.
The approval was based on data from the open-label, single-arm phase 2b TAS-120-101 trial.
Vegzelma is a vascular endothelial growth factor inhibitor.
The approval was based on data from 2 pivotal phase 3 trials, which evaluated Pedmark in pediatric patients undergoing treatment with cisplatin-based chemotherapy.
A review of geriatric assessment tools and their role in assessing older patients with cancer before and after treatment.